Lument is poised to revolutionize the landscape of abdominal CT scans by capturing market share from existing oral contrast agents. This is underpinned by the proven efficacy, high patient acceptance, minimal side effects, and user-friendly nature of the Lumentin® concept, all of which contribute to significantly enhanced diagnostic quality.
Addressable Market
The initial targeted markets are Europe, North America, and selected markets in South America.
- The estimated population in these markets in 2027 is 1.6 billion, growing below 1% per annum.
- The prevalence of relevant gastrointestinal disorders in the developed world is estimated to be 4.6% of the population per annum in 2027, and this prevalence is growing significantly.
- An estimated 60% of the population with gastrointestinal disorders is examined and diagnosed. This share is expected to increase as awareness and preventive healthcare grow.
Commercialization
Production
- An outsourced production model will be used to produce forecasted quantities with limited capital expenditure efficiently.
- Ongoing production plans with a globally renowned contract manufacturer are in place.
- The intended production partner recently indicated sufficient capacity to produce forecasted volumes at attractive prices.
Distribution
- To reach its end customers, Lument intends to engage global distribution partners with established relationships with its end customers.
- Initial solid interest and a concrete partnership proposal were received from a leading global distributor in 2023.
Assumptions
Forecasted financial development (EURm)
- Lument is expected to enter the market and commercialize Lumentin in 2027.
- The total number of abdominal CT scans in target markets (TAM), is estimated at 44m in 2027 and expected to grow 7.6% per year.
- The serviceable market (SAM) for Lument is expected to grow from 20% of TAM in 2027 to 90% in 2035 as commercial coverage expands.
- Lument is assumed to serve 20% of the SAM, increasing to 60% by 2035.
- The price for distributors is set at market levels for current market leading contrast agents.
- The production cost is based on specific quotes from Lument´s intended contract manufacturer.
- Operational costs are expected to be low and fixed as both distribution and production are outsourced.
… and the future is bright
Distinguishing itself as a pioneer, Lumentin®44 stands as the sole oral contrast agent capable of delivering MR-quality contrast using the swifter and more cost-effective CT technology. It is also foreseen that many examinations will be moved from MRI to CT catalyzing further market expansion. Additionally, the advantages of Lumentin® 44 over conventional oral agents may position it as a universal oral contrast agent for abdominal examinations across various imaging methods.
Future opportunities may also encompass the use of Lumentin® 3-D software, providing radiologists with high-resolution virtual endoscopy. Additionally, the launch of an AI initiative aims to expedite and enhance the accuracy of CT image interpretation, capitalizing on the superior quality of CT images obtained with Lumentin® 44.
Get in touch
Lument AB has its offices and labs in Lund, Sweden, the home of Lund University, IDEON Research Park, Medicon Village, and world-leading research facilities like MAX IV and European Spallation Source. We are easy to contact. Just use the form to send us a message, and we will get in touch.
Lument AB
Scheelevägen 22
Box 719
223 63 Lund
Phone +46 46 16 39 40
Email info@lumentab.com
Lument is part of the Aventure Group
www.aventureab.com